MedTrace Logo

Trop2-targeting NIR-II Molecular Probe for Breast Cancer Precise Surgery

NCT06713681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2026-04-03

No results posted yet for this study

Summary

Positive surgical margins are closely associated with local recurrence in breast-conserving surgery (BCS). Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Indocyanine green (ICG)-based the second near-infrared (NIR-II) fluorescence imaging offers real-time visualization during surgery, potentially reducing positive margin rates and improving SLN detection, while the specificity remains a challenge. Herein, the investigators will introduce a novel NIR-II probe, TTP-ICG, based on a Trop2-targeting peptide and an approach which enables rapid differentiation between cancer and para-cancer tissue as well as metastatic and normal lymph nodes. In brief, fresh tissues will be soaked in TTP-ICG immediately after resection, and their histological characterization will be determined under NIR-II fluorescence imaging. Pathological confirmation will further validate our approach.

Conditions

Interventions

DIAGNOSTIC_TEST

TTP-ICG incubation solution

Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times

Sponsors & Collaborators

  • Affiliated Cancer Hospital of Shantou University Medical College

    collaborator OTHER

  • Yunnan Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713681 on ClinicalTrials.gov